ADMA vs. FINV
ADMA (ADMA Biologics, Inc.) and FINV (FinVolution Group) are both stocks. ADMA operates in Biotechnology (Healthcare), while FINV operates in Credit Services (Financial Services). Over the past 5 years, ADMA returned 35.16%/yr vs -4.69%/yr for FINV. At a 0.14 correlation, their price movements are largely independent.
Performance
ADMA vs. FINV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ADMA achieves a -54.99% return, which is significantly lower than FINV's 2.28% return.
ADMA
- 1D
- -1.32%
- 1M
- -3.41%
- YTD
- -54.99%
- 6M
- -58.49%
- 1Y
- -61.99%
- 3Y*
- 27.09%
- 5Y*
- 35.16%
- 10Y*
- 1.84%
FINV
- 1D
- 1.62%
- 1M
- -1.18%
- YTD
- 2.28%
- 6M
- 1.69%
- 1Y
- -39.97%
- 3Y*
- 8.84%
- 5Y*
- -4.69%
- 10Y*
- —
ADMA vs. FINV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ADMA ADMA Biologics, Inc. | -54.99% | 6.36% | 279.42% | 16.49% | 175.18% | -27.69% | -51.25% | 67.36% | -25.55% | 33.75% |
FINV FinVolution Group | 2.28% | -20.07% | 45.47% | 4.39% | 6.39% | 89.23% | 8.51% | -22.85% | -49.37% | -46.54% |
Correlation
The correlation between ADMA and FINV is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.16 |
Correlation (All Time) Calculated using the full available price history since Nov 10, 2017 | 0.14 |
Fundamentals
ADMA:
$1.97B
FINV:
$1.29B
ADMA:
$0.68
FINV:
CN¥8.34
ADMA:
12.13
FINV:
4.09
ADMA:
3.93
FINV:
0.68
ADMA:
5.05
FINV:
0.54
ADMA:
$509.86M
FINV:
CN¥13.24B
ADMA:
$312.42M
FINV:
CN¥10.21B
ADMA:
$218.74M
FINV:
CN¥2.61B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ADMA vs. FINV — Risk / Return Rank
ADMA
FINV
ADMA vs. FINV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ADMA Biologics, Inc. (ADMA) and FinVolution Group (FINV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ADMA | FINV | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.32 | ||
| Sortino ratioReturn per unit of downside risk | -0.72 | ||
| Omega ratioGain probability vs. loss probability | 0.76 | 0.87 | -0.11 |
| Calmar ratioReturn relative to maximum drawdown | -0.98 | -0.71 | -0.27 |
| Martin ratioReturn relative to average drawdown | -1.95 | -0.96 | -0.99 |
Loading charts...
Drawdowns
ADMA vs. FINV - Drawdown Comparison
The maximum ADMA drawdown since its inception was -91.28%, roughly equal to the maximum FINV drawdown of -89.76%. Use the drawdown chart below to compare losses from any high point for ADMA and FINV.
Loading charts...
Drawdown Indicators
| ADMA | FINV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.28% | -89.76% | -1.52% |
Max Drawdown (1Y)Largest decline over 1 year | -63.48% | -56.42% | -7.06% |
Max Drawdown (3Y)Largest decline over 3 years | -68.99% | -56.42% | -12.57% |
Max Drawdown (5Y)Largest decline over 5 years | -68.99% | -70.54% | +1.55% |
Max Drawdown (10Y)Largest decline over 10 years | -86.11% | — | — |
Current DrawdownCurrent decline from peak | -66.50% | -49.54% | -16.96% |
Average DrawdownAverage peak-to-trough decline | -53.05% | -54.09% | +1.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 33.85% | 41.69% | -7.84% |
Volatility
ADMA vs. FINV - Volatility Comparison
The current volatility for ADMA Biologics, Inc. (ADMA) is 9.74%, while FinVolution Group (FINV) has a volatility of 19.10%. This indicates that ADMA experiences smaller price fluctuations and is considered to be less risky than FINV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ADMA | FINV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.74% | 19.10% | -9.36% |
Volatility (6M)Calculated over the trailing 6-month period | 45.54% | 33.29% | +12.25% |
Volatility (1Y)Calculated over the trailing 1-year period | 54.60% | 48.91% | +5.69% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 59.47% | 49.99% | +9.48% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 69.03% | 71.75% | -2.72% |
Dividends
ADMA vs. FINV - Dividend Comparison
ADMA has not paid dividends to shareholders, while FINV's dividend yield for the trailing twelve months is around 6.08%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
ADMA ADMA Biologics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
FINV FinVolution Group | 6.08% | 5.30% | 3.49% | 4.39% | 4.13% | 3.45% | 4.49% | 7.17% |
Financials
ADMA vs. FINV - Financials Comparison
This section allows you to compare key financial metrics between ADMA Biologics, Inc. and FinVolution Group. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ADMA vs. FINV - Profitability Comparison
ADMA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a gross profit of 80.75M and revenue of 114.49M. Therefore, the gross margin over that period was 70.5%.
FINV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, FinVolution Group reported a gross profit of 2.43B and revenue of 3.19B. Therefore, the gross margin over that period was 76.3%.
ADMA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported an operating income of 58.27M and revenue of 114.49M, resulting in an operating margin of 50.9%.
FINV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, FinVolution Group reported an operating income of 526.49M and revenue of 3.19B, resulting in an operating margin of 16.5%.
ADMA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a net income of 45.33M and revenue of 114.49M, resulting in a net margin of 39.6%.
FINV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, FinVolution Group reported a net income of 412.55M and revenue of 3.19B, resulting in a net margin of 12.9%.
Frequently Asked Questions
ADMA and FINV have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
FINV has higher volatility (19.10%) compared to ADMA (9.74%). In terms of maximum drawdown, ADMA dropped -91.28% vs FINV's -89.76%.
FINV currently has the higher Sharpe Ratio (-0.82 vs -1.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ADMA and FINV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer